Rabaglio, Manuela
Sun, Zhuoxin
Maibach, Rudolf
Giobbie-Hurder, Anita
Ejlertsen, Bent
Harvey, Vernon J.
Neven, Patrick
Láng, István
Bonnefoi, Hervé
Wardley, Andrew
Ruepp, Barbara
Castiglione, Monica
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Colleoni, Marco
Thürlimann, Beat
Regan, Meredith M. http://orcid.org/0000-0002-2428-6109
Funding for this research was provided by:
Novartis
The Swedish Cancer Society
The Swedish Research Council
The Cancer Council Australia
Australia New Zealand Breast Cancer Trials Group
Frontier Science and Technology Research Foundation
Swiss Group for Clinical Cancer Research
Cancer Research Switzerland
Oncosuisse
The Foundation for Clinical Cancer Research of Eastern Switzerland
Article History
Received: 11 August 2020
Accepted: 13 October 2020
First Online: 7 November 2020
Compliance with ethical standards
:
: Manuela Rabaglio declares that she has no conflict of interest. Zhuoxin Sun declares that she has no conflict of interest. Rudolf Maibach declares that he has no conflict of interest. Anita Giobbie-Hurder reports that her institution receives support for her salary from nine National Institutes of Health (NIH) grants, including 5R01 CA193970-05, 1U24 CA224316-01, 1U24 CA224331-01, 5R01 CA229851-03, 5R01 CA190838-04, 5R01 CA221874-03, 1R01 CA244975-01, 1R01 CA252312-01, and 1R01 CA251599-01 in addition two other grants from the Susan Smith Center for Women’s Cancer and the Melanoma Research Alliance. Bent Ejlertsen reports that his institution receives research funding from AstraZeneca, Nanostring Technologies, Novartis, Pfizer, Roche, Samsung, and Venture Oncology. Vernon J. Harvey declares that he has no conflict of interest. Patrick Neven declares that he has no conflict of interest. István Láng declares that he has no conflict of interest. Hervé Bonnefoi declares that he has no conflict of interest. Andrew Wardley declares that he has no conflict of interest. Barbara Ruepp declares that she has no conflict of interest. Monica Castiglione declares that she has no conflict of interest. Alan S. Coates declares that he has no conflict of interest. Richard D. Gelber reports that his institution receives partial support for his salary from AstraZeneca, Celgene, Ferring, Ipsen, Merck, Novartis, Pfizer, and Roche. Marco Colleoni reports that he receives an honorarium from Novartis. Beat Thürlimann receives consultation fees from Amgen, AstraZeneca, Eli Lilly, Roche, and Pfizer, owns stocks in Novartis and Roche, holds leadership roles at the Swiss Cancer Research Foundation, Rising Tide for Clinical Cancer Research Foundation, Swiss Society of Senology Board of Directors, IBCSG Scientific Committee, IBCSG Biology Project Working Group, Cancer League of Eastern Switzerland Board of Directors, Swiss Foundation for Clinical Cancer Research Executive Committee, and is the Former SAKK President. Meredith M. Regan receives research funding (to the institution) from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bayer, and Bristol-Myers Squibb and receives consulting/advisory fees from Ipsen/Debiopharm (institution IBCSG), Bristol-Myers Squibb, and Tolmar Pharmaceuticals.
: Ethics committees and relevant health authorities approved the protocol.
: Written informed consent was obtained from all individual participants included in this study.